Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Reply to “Properties of a disease-specific prion probe”

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

References

  1. Paramithiotis, E. et al. Nat. Med. 9, 893–899 (2003).

    Article  CAS  Google Scholar 

  2. Korth, C. et al. Nature 390, 74–77 (1997).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

This response letter represents an ongoing University-Industry collaboration between scientists at the University of Toronto and two biotechnology companies (Caprion Pharmaceuticals of Montreal, Canada, and Idexx Laboratories of Portland, Maine). N.R.C., the senior author, is a professor at the University of Toronto, as well as 'Founder and Scientific Advisor' of Caprion Pharmaceuticals, from which he has derived partial salary and laboratory operating grants. The commercial aspects of this discovery are being developed under license from Caprion to Idexx and Ortho Clinical Diagnostics.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Paramithiotis, E., Pinard, M., Lawton, T. et al. Reply to “Properties of a disease-specific prion probe”. Nat Med 10, 11–12 (2004). https://doi.org/10.1038/nm0104-11b

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0104-11b

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing